Published in J Biol Chem on July 06, 2007
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol (2010) 3.32
The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci (2009) 2.80
Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol (2010) 2.08
An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med (2014) 1.99
The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener (2007) 1.81
Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol (2014) 1.76
beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics (2008) 1.74
A G-rich element forms a G-quadruplex and regulates BACE1 mRNA alternative splicing. J Neurochem (2012) 1.70
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A (2011) 1.67
Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J (2008) 1.60
The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J Biol Chem (2008) 1.57
miR-186 is decreased in aged brain and suppresses BACE1 expression. J Neurochem (2016) 1.49
Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron (2008) 1.49
Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem (2014) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 1.33
Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J Neurochem (2010) 1.33
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest (2012) 1.32
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther (2014) 1.30
Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem (2010) 1.28
ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron (2013) 1.25
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol Dis (2011) 1.13
The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem (2012) 1.13
Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation. Mol Neurodegener (2013) 1.11
Phospho-eIF2α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One (2010) 1.11
Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites. J Neurosci (2009) 1.10
Trafficking regulation of proteins in Alzheimer's disease. Mol Neurodegener (2014) 1.08
Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice. Eur J Neurosci (2009) 1.07
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Reduced sodium channel Na(v)1.1 levels in BACE1-null mice. J Biol Chem (2010) 1.05
BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener (2010) 1.05
β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem (2012) 1.05
Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein. J Biol Chem (2012) 0.97
beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein. J Biol Chem (2009) 0.96
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem (2012) 0.96
Depletion of GGA1 and GGA3 mediates postinjury elevation of BACE1. J Neurosci (2012) 0.95
Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes. Am J Med Genet B Neuropsychiatr Genet (2010) 0.94
High-density lipoprotein facilitates in vivo delivery of α-tocopherol-conjugated short-interfering RNA to the brain. Hum Gene Ther (2011) 0.90
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics (2007) 0.90
Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence. J Alzheimers Dis (2012) 0.88
Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. PLoS One (2009) 0.88
Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. Mol Brain (2014) 0.88
Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med (2010) 0.87
BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis (2011) 0.87
Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem (2011) 0.86
The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease. Future Sci OA (2015) 0.86
Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett (2008) 0.86
Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci (2014) 0.85
Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther (2014) 0.85
Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1. J Biol Chem (2015) 0.84
Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin. Exp Brain Res (2011) 0.84
Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta (2011) 0.84
Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease. Transl Psychiatry (2013) 0.84
BACE1 protein endocytosis and trafficking are differentially regulated by ubiquitination at lysine 501 and the Di-leucine motif in the carboxyl terminus. J Biol Chem (2012) 0.84
Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener (2015) 0.83
Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem (2010) 0.83
Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis (2014) 0.83
RNA interference-mediated silencing of BACE and APP attenuates the isoflurane-induced caspase activation. Med Gas Res (2011) 0.81
Bioinformatics identification of modules of transcription factor binding sites in Alzheimer's disease-related genes by in silico promoter analysis and microarrays. Int J Alzheimers Dis (2011) 0.81
Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int (2014) 0.81
Linking vascular disorders and Alzheimer's disease: potential involvement of BACE1. Neurobiol Aging (2008) 0.81
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Mol Neurodegener (2015) 0.80
Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression. Curr Alzheimer Res (2015) 0.79
BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. Curr Alzheimer Res (2013) 0.78
The normal and pathologic roles of the Alzheimer's β-secretase, BACE1. Curr Alzheimer Res (2014) 0.78
Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. Neurosci Biobehav Rev (2016) 0.78
The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation. PLoS One (2015) 0.77
The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor. Nutrients (2016) 0.77
A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Mol Brain (2015) 0.77
Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease. Acta Neuropathol (2016) 0.77
Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages. Neuroscience (2015) 0.77
A peptide binding to the β-site of APP improves spatial memory and attenuates Aβ burden in Alzheimer's disease transgenic mice. PLoS One (2012) 0.76
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J Alzheimers Dis (2016) 0.76
Decreasing the expression of PICALM reduces endocytosis and the activity of β-secretase: implications for Alzheimer's disease. BMC Neurosci (2016) 0.76
AβPP-selective BACE inhibitors (ASBI): novel class of therapeutic agents for alzheimer's disease. J Alzheimers Dis (2013) 0.76
Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice. Front Aging Neurosci (2015) 0.76
Oxygen-glucose deprivation regulates BACE1 expression through induction of autophagy in Neuro-2a/APP695 cells. Neural Regen Res (2015) 0.76
Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol Aging (2015) 0.76
Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Curr Neuropharmacol (2011) 0.76
High glucose upregulates BACE1-mediated Aβ production through ROS-dependent HIF-1α and LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells. Sci Rep (2016) 0.75
Alteration of Aβ metabolism-related molecules in predementia induced by AlCl3 and D-galactose. Age (Dordr) (2009) 0.75
Silencing of amyloid precursor protein expression using a new engineered delta ribozyme. Int J Alzheimers Dis (2012) 0.75
Differential contributions of ApoE4 and female sex to BACE1 activity and expression mediate Aβ deposition and learning and memory in mouse models of Alzheimer's disease. Front Aging Neurosci (2015) 0.75
Rafts, Nanoparticles and Neural Disease. Nanomaterials (Basel) (2012) 0.75
Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels. Nutrients (2017) 0.75
Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors. PLoS One (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making (2006) 3.50
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
Development and mapping of SSR markers for maize. Plant Mol Biol (2002) 2.83
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol (2004) 2.54
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
Guidelines for submitting adverse event reports for publication. Drug Saf (2007) 2.38
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med (2008) 2.37
Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci (2002) 2.35
Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A (2004) 2.27
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res (2012) 2.25
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
US Features of thyroid malignancy: pearls and pitfalls. Radiographics (2007) 2.18
Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science (2009) 2.13
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci (2004) 2.07
Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol (2006) 1.96
Reconstitution of ThiC in thiamine pyrimidine biosynthesis expands the radical SAM superfamily. Nat Chem Biol (2008) 1.96
Genetic dissection of intermated recombinant inbred lines using a new genetic map of maize. Genetics (2006) 1.89
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci U S A (2003) 1.86
Diphthamide biosynthesis requires an organic radical generated by an iron-sulphur enzyme. Nature (2010) 1.85
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.85
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry (2006) 1.78
Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis (2008) 1.77
A multicenter randomized comparison of the Endocapsule and the Pillcam SB. Gastrointest Endosc (2008) 1.74
Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci (2008) 1.70
Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A (2013) 1.62
Contralateral effects of unilateral strength training: evidence and possible mechanisms. J Appl Physiol (1985) (2006) 1.58
Adjacent level ossification development after anterior cervical fusion without plate fixation. Spine (Phila Pa 1976) (2009) 1.55
Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem (2008) 1.54
Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement (2013) 1.51
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol (2005) 1.51
Drosophila neuromuscular synapse assembly and function require the TGF-beta type I receptor saxophone and the transcription factor Mad. J Neurobiol (2003) 1.47
Anatomic considerations for the placement of C2 laminar screws. Spine (Phila Pa 1976) (2006) 1.46
Integrating clinical practice and public health surveillance using electronic medical record systems. Am J Prev Med (2012) 1.46
Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci (2002) 1.44
Editorial comment to standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates. Int J Urol (2013) 1.41
Oral cancer campaign. J Am Dent Assoc (2002) 1.39
Penetration of Günther Tulip filter struts through an introducer sheath: case report and safety concerns. J Vasc Interv Radiol (2009) 1.38
Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A (2003) 1.37
Animal models of PD: pieces of the same puzzle? Neuron (2002) 1.34
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis (2006) 1.32
Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem (2011) 1.29
Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun (2006) 1.29
Returning to learning following a concussion. Pediatrics (2013) 1.28
Relief as a reward: hedonic and neural responses to safety from pain. PLoS One (2011) 1.24
Long-term posttraumatic stress disorder persists after major trauma in adolescents: new data on risk factors and functional outcome. J Trauma (2005) 1.24
A GeneTrek analysis of the maize genome. Proc Natl Acad Sci U S A (2007) 1.23
Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf (2007) 1.23
Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci U S A (2004) 1.20
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin (2008) 1.18
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol (2003) 1.17
BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol Aging (2007) 1.17
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci (2012) 1.16
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement (2013) 1.16
Mutations in RRM4 uncouple the splicing repression and RNA-binding activities of polypyrimidine tract binding protein. RNA (2002) 1.15
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol (2004) 1.11
Reassessment of the reaction mechanism in the heme dioxygenases. J Am Chem Soc (2009) 1.11
Constitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains. Infect Immun (2008) 1.11
Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med (2011) 1.10
Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem (2010) 1.09
Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. J Neurosci (2008) 1.08
Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One (2012) 1.08
The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function. Biochem Pharmacol (2011) 1.06
Ultrashort-echo time MR imaging of the patella with bicomponent analysis: correlation with histopathologic and polarized light microscopic findings. Radiology (2012) 1.06
Unilateral practice of a ballistic movement causes bilateral increases in performance and corticospinal excitability. J Appl Physiol (1985) (2008) 1.03
Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis (2008) 1.03
Evidence for a high-spin Fe(IV) species in the catalytic cycle of a bacterial phenylalanine hydroxylase. Biochemistry (2011) 1.03
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03
Febrile infants with urinary tract infections at very low risk for adverse events and bacteremia. Pediatrics (2010) 1.02
Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci (2007) 1.02
Genotyping by RAD sequencing enables mapping of fatty acid composition traits in perennial ryegrass (Lolium perenne (L.)). Plant Biotechnol J (2013) 1.01
Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. J Biol Chem (2003) 1.01
Integrating clinical practice and public health surveillance using electronic medical record systems. Am J Public Health (2012) 1.01
Human beta-secretase (BACE) and BACE inhibitors. J Med Chem (2003) 1.00